NetworkNewsBreaks – Cybin Inc. (NYSE American: C
Post# of 341
(Total Views: 131)
Posted On: 04/25/2024 4:13:41 PM
NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. According to the announcement, Doug Drysdale, Cybin CEO, will appear on a panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024, at 10:00 am PDT. “The Conference provides a meaningful platform to exchange ideas with global thought leaders and share our vision for transforming the treatment paradigm for mental health. With the recent receipt of FDA Breakthrough Therapy Designation for CYB003, our deuterated psilocybin analog for the adjunctive treatment of major depressive disorder entering a Phase 3 trial around mid-year; and CYB004, our deuterated DMT program in Phase 2 development for the treatment of generalized anxiety disorder, we are excited to share the groundbreaking work that Cybin is carrying out with the goal of bringing improved therapeutic options for treating mental health conditions,” said Doug Drysdale.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. According to the announcement, Doug Drysdale, Cybin CEO, will appear on a panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024, at 10:00 am PDT. “The Conference provides a meaningful platform to exchange ideas with global thought leaders and share our vision for transforming the treatment paradigm for mental health. With the recent receipt of FDA Breakthrough Therapy Designation for CYB003, our deuterated psilocybin analog for the adjunctive treatment of major depressive disorder entering a Phase 3 trial around mid-year; and CYB004, our deuterated DMT program in Phase 2 development for the treatment of generalized anxiety disorder, we are excited to share the groundbreaking work that Cybin is carrying out with the goal of bringing improved therapeutic options for treating mental health conditions,” said Doug Drysdale.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)